Eden BioSolutions (LSE:EDEN), the biopesticides developer formerly trading under a different name, has secured a significant regulatory milestone in the United States. On 13 November 2026 the company announced that the US Environmental Protection Agency had granted unconditional federal registration for Mevalone Delta, opening the way for sales in the world's largest agricultural market once state-level registrations are in place.
What the company does
Eden develops and supplies biopesticides and microencapsulation technology for crop protection, animal health and consumer products. Its flagship product is Mevalone, a plant-derived biofungicide used against diseases such as powdery and downy mildew in grapes. Other products include Cedroz, a bionematicide, and Ecovelex, a bird-repellent seed treatment for maize. The company works through partners including Corteva, Syngenta, Eastman Chemical and Sipcam.
The company changed its name to Eden BioSolutions plc on 30 September 2026, with trading under the new name starting on 1 October. Its AIM ticker, EDEN, was unchanged.
Latest developments
According to the 13 November announcement, the registration allows US sales to begin, although state registrations are still required and are expected to take between one and twelve months. The approved label covers crops with a combined US farm-gate value of about US$33 billion in 2024. Eden estimates the US addressable market at about US$144 million and expects to reach roughly 3% Market Share at peak sales. The product can be applied up to three days before harvest, and Sipcam Agro USA will distribute it.
This followed a separate announcement on 28 September 2026 that the EPA had approved an expanded label for Mevalone. In August the company reported regulatory approvals in Slovakia and Egypt.
Financial and Dividend picture
Eden's preliminary results, published on 26 August 2026, covered a 15-month period to 31 March 2026 after a change of year end, so comparisons with the prior 12-month period are not like for like. Revenue was £4.85 million, against £4.30 million previously, and the loss after tax was £2.45 million. Cash at the end of the period was £1.52 million, but the company said it had completed a fundraise of £10.8 million gross, of which £7.6 million was received after the period end. Eden does not pay a dividend.
The board said its full-year expectations were unchanged but depended on stocking of Mevalone for the 2027 season and potential upside from Ecovelex. It also said it was negotiating with two lead candidates over its insecticide and expected to sign an agreement by the end of 2026.
Sector and index context
Eden is one of the agricultural technology names in the FTSE AIM All Share Index. Biological crop protection products are attracting interest as regulators restrict some synthetic chemicals and growers look for residue-friendly alternatives, but the market remains small relative to conventional agrochemicals and depends heavily on partner distribution.
Key risks
The company has warned that hot, dry weather in Europe and the US can reduce Mevalone use and leave distributors holding unsold stock, which affects reorders. Regulatory processes are slow and uncertain, as the state-level timetable for Mevalone Delta shows. Eden relies on large partners for commercialisation, and its revenue base is still small, so delays can have an outsized effect on results.
What to watch next
Investors will watch for state registrations and first US sales of Mevalone Delta, the expected insecticide agreement by the end of 2026, an update on season-end Mevalone sales and progress towards full approval of Ecovelex.






Please wait processing your request...